ABUS vs RUN
Arbutus Biopharma Corp (ABUS) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the ABUS and RUN stock pages for the full models.
Not investment advice.